This not only stresses the usefulness of the technology for blood-based and brain biomarker levels during the early and late stages of rmTBI but also continues to implicate the usefulness of P-tau as a blood-derived biomarker not only for TBI (36) but also preclinically and clinically for tauopathies such as AD, frontotemporal lobar degeneration and CTE. This evidence concerns the gene MAPT and Alzheimer disease.